VIVA BIOTECH (01873) jumped nearly 7% in afternoon trading, rising 6.42% to HK$2.82 with trading volume reaching HK$34.55 million as of press time.

On the news front, VIVA BIOTECH recently released its interim results, reporting revenue of RMB 832 million, a year-on-year decrease of 15.27%, while profit attributable to shareholders reached RMB 122 million, representing a year-on-year increase of 4.28%. According to the announcement, the group's gross margin stood at 40.8%, up 6.3 percentage points compared to the same period last year. This improvement was primarily attributed to the optimization and adjustment of Langhua's business structure, enhanced operational efficiency in CRO business, and contributions from the growth of new business segments.

It has been noted that VIVA BIOTECH began its AI drug development layout five years ago. Currently, AI-related orders account for 12% of newly signed contracts and show a growing trend. The company's AIDD and CADD platforms possess capabilities in proprietary algorithm development and platform construction, have experience in developing various drug forms, and fully leverage VIVA's structure-based drug development advantages. Building on this foundation, VIVA is transitioning from a stage focused primarily on empowering various drug development phases through computational methods to a new phase of AI-driven drug design that transforms drug design paradigms.